Kevin is Executive Vice President, Research and Development for Jasper Therapeutics, a biotechnology company developing and commercializing safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. He is also adjunct professor of medicine at Yale School of Medicine. In previous roles, Kevin served as Chief Medical Officer at NextCure and Vice President and head of antibody clinical development at Incyte. He joined Incyte from AstraZeneca, where he was Senior Medical Director, overseeing global medicines development in oncology. Kevin began his biopharma industry experience at Bristol Myers Squibb, where he led early development programs and was responsible for authoring and managing first-in-human clinical trials. Kevin received his B.S. in Molecular Biophysics and Biochemistry from Yale University and his M.D. from George Washington University.